Company intelligence
Portal
About Portal
Portal is building the universal infrastructure for cell engineering across drug discovery and cell therapy. Our proprietary mechanical system enables efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across many cell types and workflows. With more than 100 customer sites including the top 10 pharma, researchers use Portal to run high-throughput, physiologically relevant screens and de-risk targets earlier, while cell therapy developers leverage the platform to multi-engineer cells beyond the limits of viral or electroporation methods. Integrated with leading high-throughput robotics and with GMP manufacturing systems, Portal is powering both next-generation discovery and laying the groundwork for future point-of-care cell therapy manufacturing.
Verified activity
Signals from Portal
3 published signals
Presence & Recognition
Portal hosted two partner training visits this week to explore cell engineering tech in life sciences.
Reported by Xinyi Feng
People
Portal welcomed Xinyi Feng as a Scientist in the first month.
Reported by Xinyi Feng
Capital & Finance
Portal was awarded $2M from the National Center for Advancing Translational Sciences (NCATS) to expand applications of Galaxy-i, its high-throughput screening platform.
Reported by Portal